ABBV vs MRK
AbbVie Inc. and Merck & Co. Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | ABBV | MRK |
|---|---|---|
| Revenue | $61.2B | $65.0B |
| Net income | $4.2B | $18.3B |
| Gross margin | 70.2% | 74.8% |
| Net margin | 6.9% | 28.1% |
| Return on equity | · | 36.9% |
| Diluted EPS | $2.36 | $7.28 |
| Dividend / share | $6.65 | $3.28 |
| Payout ratio | 275.8% | 44.8% |
| Free cash flow | $17.8B | $12.4B |
| Equity | $-3.3B | $52.6B |
| Net debt / equity | · | 0.66× |
| Current ratio | 0.67× | 1.54× |
| Revenue CAGR 5y | 6.0% | 9.4% |
| Profit CAGR 5y | −1.7% | 20.9% |
ABBV and MRK book revenue within 15% of each other, and MRK keeps more of each dollar of revenue as profit (28.1% against 6.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ABBV | MRK |
|---|---|---|
| FY2025 | $61.2B | $65.0B |
| FY2024 | $56.3B | $64.2B |
| FY2023 | $54.3B | $60.1B |
| FY2022 | $58.1B | $59.3B |
| FY2021 | $56.2B | $48.7B |
| FY2020 | $45.8B | $41.5B |
| FY2019 | $33.3B | $39.1B |
| FY2018 | $32.8B | $42.3B |
| FY2017 | $28.2B | $40.1B |
| FY2016 | $25.6B | $39.8B |
Bottom line
| Fiscal year | ABBV | MRK |
|---|---|---|
| FY2025 | $4.2B | $18.3B |
| FY2024 | $4.3B | $17.1B |
| FY2023 | $4.9B | $365.0M |
| FY2022 | $11.8B | $14.5B |
| FY2021 | $11.5B | $13.0B |
| FY2020 | $4.6B | $7.1B |
| FY2019 | $7.9B | $9.8B |
| FY2018 | $5.7B | $6.2B |
| FY2017 | $5.3B | $2.4B |
| FY2016 | $6.0B | $3.9B |
15 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$3,851,000,000 | MRK |
| FY2024 | −$7,834,000,000 | MRK |
| FY2023 | −$5,797,000,000 | MRK |
| FY2022 | −$1,229,000,000 | MRK |
| FY2021 | +$7,493,000,000 | ABBV |
| FY2020 | +$4,286,000,000 | ABBV |
| FY2019 | −$5,855,000,000 | MRK |
| FY2018 | −$9,541,000,000 | MRK |
| FY2017 | −$11,906,000,000 | MRK |
| FY2016 | −$14,169,000,000 | MRK |
| FY2015 | −$16,639,000,000 | MRK |
| FY2014 | −$22,277,000,000 | MRK |
| FY2013 | −$25,243,000,000 | MRK |
| FY2012 | −$28,887,000,000 | MRK |
| FY2011 | −$30,603,000,000 | MRK |
The higher-revenue side has changed between ABBV and MRK over this period. The gap has narrowed since the earliest year compared.
15 of 19 comparable fiscal years — a year missing data on either side is not counted.
12 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −21.2 pp | MRK |
| FY2024 | −19.1 pp | MRK |
| FY2023 | +8.3 pp | ABBV |
| FY2022 | −4.1 pp | MRK |
| FY2021 | −6.2 pp | MRK |
| FY2020 | −7.0 pp | MRK |
| FY2019 | −1.3 pp | MRK |
| FY2018 | +2.7 pp | ABBV |
| FY2017 | +12.8 pp | ABBV |
| FY2016 | +13.3 pp | ABBV |
| FY2015 | +11.2 pp | ABBV |
| FY2014 | −19.4 pp | MRK |
The higher net margin has changed hands between ABBV and MRK over this period.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRK's net margin has been more volatile than ABBV's over the 12 comparable fiscal years — 9.2 percentage points of standard deviation against 6.4.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ABBV and MRK over these 12 fiscal years — ABBV led in 5 and MRK in 7.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ABBV's return on equity has been more volatile than MRK's over the 8 comparable fiscal years — 45.0 percentage points of standard deviation against 15.3.
8 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
ABBV led in return on equity in every one of the 8 comparable fiscal years — a structural lead, not a recent swing.
8 of 18 comparable fiscal years — a year missing data on either side is not counted.